Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21
| Autor: | Agathoklis Tsatsoulis, Michail I. Papafaklis, Antonios P. Vlahos, Katerina K. Naka, Eleni M Domouzoglou, Lampros K. Michalis, Eleftheria Maratos-Flier |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
FGF21 Physiology Neovascularization Physiologic Disease Coronary Artery Disease Review Biology Bioinformatics Fibroblast growth factor Coronary artery disease Physiology (medical) Internal medicine medicine Glucose homeostasis Humans Therapeutic angiogenesis Vascular disease medicine.disease Atherosclerosis Plaque Atherosclerotic Biomarker (cell) Fibroblast Growth Factors Endocrinology Cardiovascular Diseases Endothelium Vascular Cardiology and Cardiovascular Medicine |
| Zdroj: | American journal of physiology. Heart and circulatory physiology. 309(6) |
| ISSN: | 1522-1539 |
| Popis: | Early detection of risk factors for enhanced primary prevention and novel therapies for treating the chronic consequences of cardiovascular disease are of the utmost importance for reducing morbidity. Recently, fibroblast growth factors (FGFs) have been intensively studied as potential new molecules in the prevention and treatment of cardiovascular disease mainly attributable to metabolic effects and angiogenic actions. Members of the endocrine FGF family have been shown to increase metabolic rate, decrease adiposity, and restore glucose homeostasis, suggesting a multiple metabolic role. Serum levels of FGFs have been associated with established cardiovascular risk factors as well as with the severity and extent of coronary artery disease and could be useful for prediction of cardiovascular death. Furthermore, preclinical investigations and clinical trials have tested FGF administration for therapeutic angiogenesis in ischemic vascular disease, demonstrating a potential role in improving angina and limb function. FGF21 has lately emerged as a potent metabolic regulator with multiple effects that ultimately improve the lipoprotein profile. Early studies show that FGF21 is associated with the presence of atherosclerosis and may play a protective role against plaque formation by improving endothelial function. The present review highlights recent investigations suggesting that FGFs, in particular FGF21, may be useful as markers of cardiovascular risk and may also serve as protective/therapeutic agents in cardiovascular disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|